|
71 |
Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC
Enthalten in Analytical and bioanalytical chemistry Bd. 414, 27.7.2022, Nr. 23, date:9.2022: 6761-6769
|
|
|
|
72 |
Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Enthalten in Advances in therapy Bd. 39, 30.8.2022, Nr. 11, date:11.2022: 5300
|
|
|
|
73 |
Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
Enthalten in Advances in therapy Bd. 38, 19.7.2021, Nr. 8, date:8.2021: 4602
|
|
|
|
74 |
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
Enthalten in Advances in therapy Bd. 36, 30.5.2019, Nr. 8, date:8.2019: 2086-2095
|
|
|
|
75 |
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
Enthalten in BioDrugs Bd. 35, 11.5.2021, Nr. 4, date:7.2021: 469-471
|
|
|
|
76 |
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Enthalten in Advances in therapy Bd. 39, 23.6.2022, Nr. 8, date:8.2022: 3711-3734
|
|
|
|
77 |
Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety
Enthalten in Drugs - real world outcomes Bd. 7, 22.4.2020, Nr. 2, date:6.2020: 131-139
|
|
|
|
78 |
Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
Enthalten in Arthritis Research & Therapy Bd. 27, 17.7.2025, Nr. 1, date:12.2025: 1-7
|
|
|
|
79 |
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Enthalten in Advances in therapy Bd. 36, 5.6.2019, Nr. 8, date:8.2019: 1851-1877
|
|
|
|
80 |
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
Enthalten in Drug safety Bd. 42, 21.6.2019, Nr. 12, date:12.2019: 1437-1447
|
|
Administration
